Comparison of efficacy of topical tazarotene with topical adapalene in the treatment of facial acne vulgaris
DOI:
https://doi.org/10.66344/jpad.v32i3.1929Abstract
Background Acne is characterized by chronic inflammation of pilosebaceous units. It is characterized by seborrhea, comedones, papules, pustules, nodules, pseudocysts that may lead to scar formation.1 Types of acne include acne vulgaris, acne fulminans, acne conglobata, occupational acne, prepubertal acne. Acne commonly affects adolescents and adults; affecting more than 85% of adolescents.2 This study will give us local statistics of efficacy of topical adapalene vs. topical tazarotene for treating facial acne vulgaris and the results of this study will be used as evidence for future research and treatment recommendations for facial acne vulgaris.
Objective Comparison of efficacy of topical tazarotene vs. topical adapalene for treating facial acne vulgaris.
Methods In this study 44 patients were included in each group. In group A, patients were subjected to topical tazarotene gel (0.1%) thrice daily for 4 weeks (amount pea size) while patients in group B were subjected topical adapalene gel (0.1%) three times a day for 4 weeks (amount pea size). All patients were followed 4 weeks after start of therapy. Treatment was considered effective if there is at least 50% reduction in number of lesions from baseline.
Results In Group A mean age was 28±12.15 years while in Group B mean age was 26±11.84 years. There were 18 (41%) males and 26 (59%) females in Group A and there were 17 (39%) males and 27 (61%) females in Group B. Tazarotene gel was effective in 29 (66%) patients while adapalene gel was effective in 27 (61%) patients.
Conclusion Our study concludes that topical tazarotene gel was more effective than topical adapalene (66% vs. 61%) in the treating facial acne vulgaris.
References
1. Layton AM. Disorders of the Sebaceous Glands. In: Burns T, Breathnach S Cox N, Griffiths C Editors. Rooks Text Book of Dermatology 8th edition. Oxford; Wiley-Blackwell Scientific Publications; 2010. p42.17.
2. James WD Clinical practice. Acne. N Engl J Med. 2005;352:1463-72.
3. Aktans, Ozmen E, Sanli B Anxiety,Depression and Nature of Acne vulgaris in Adolescents. Int J Dermatol. 2000;39:354-7.
4. Burris J, Rietkerk W, Woolf K. Relationships of self-reported dietary factors and perceived acne severity in a cohort of New York young adults. J Acad Nutr Diet. 2014;114:384-92.
5. Eichenfield LF, Krakowski AC, Piggott C. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics. 2013;131(suppl 3):S163-86.
6. Khodaeiani E, Fouladi RF, Amirnia M, Saeidi M, Karimi ER. Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris. Int J Dermatol, 2013;52:999-1004.
7. Yeh L, Bonati LM, Silverberg NB. Topical retinoids for acne. Semin Cutan Med Surg. 2016;35(2):50-6.
8. Ahmed I, Sarwar M. Topical adapalene cream 0.1% v/s isotretinoin 0.05% in the treatment of acne vulgaris: a randomized open-label clinical trial. J Pak Assoc Dermatol. 2016;19(1):23-5.
9. Gregoriou S, Kritsotaki E, Katoulis A, Rigopoulos D. Use of tazarotene foam for the treatment of acne vulgaris. Clin Cosmet Investig Dermatol. 2014;7:165-70.
10. Del Rosso JQ, Tanghetti E. A status report on topical tazarotene in the management of acne vulgaris. J Drugs Dermatol. 2013;12(3):s53-8.
11. Khurshid K, Pal SS. Comparison of efficacy and tolerability of topical 0.1% adapalene gel with 0.05% isotretinoin gel in the treatment of acne vulgaris. J Pak Assoc Dermatol. 2012;22(3):240-7.
12. Swaroop MR. A Comparative Study of Efficacy of once Daily 0.1% Tazarotene and Adapalene Gel for the Treatment of Facial Acne Vulgaris. Ind J Clin Exp Dermatol. 2015;1(1):4-8.
13. Rahman MH, Sikder MS, Khondker L. Efficacy and tolerability of 0.1% tazarotene cream and 0.05% tretinoin cream in the treatment of acne vulgaris. Bang Sheikh Mujib Med Univ J. 2016;8(1):24-9.
14. Tanghetti E, Dhawan S, Green L, Del Rosso J, Draelos Z, Leyden J, Shalita A, Glaser DA, Grimes P, Webster G, Barnett P, Le Gall N. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris. J Drugs Dermatol. 2010;9(5):549-58.
15. Webster GF, Guenther L, Poulin YP, Solomon BA, Loven K, Lee J. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Cutis. 2002;69(2 Suppl):4-11.
16. Khurshid K, Pal SS. Comparison of efficacy and tolerability of topical 0.1% adapalene gel with 0.05% isotretinoin gel in the treatment of acne vulgaris. J Pak Assoc Dermatol. 2012;22(3):240-47.
17. Swaroop MR. A Comparative Study of Efficacy of once Daily 0.1% Tazarotene and Adapalene Gel for the Treatment of Facial Acne Vulgaris. Ind J Clin Exp Dermatol. 2015;1(1):4-8.
18. Rahman MH, Sikder MS, Khondker L. Efficacy and tolerability of 0.1% tazarotene cream and 0.05% tretinoin cream in the treatment of acne vulgaris. Bang Sheikh Mujib Med Univ J. 2016;8(1):24-9.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 farah sagheer, Mohammad majid paracha, sassi jokhio, Sadia Naseem
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
